α-Tocopheryl Succinate Affects Malignant Cell Viability, Proliferation, and Differentiation

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Malignant tumors are a significant global health concern, driving the search for novel antitumor agents.
• The vitamin E family, particularly alpha-tocopheryl succinate (vitamin E succinate, VES), has demonstrated notable antitumor potential.
• Existing treatments often have severe side effects on normal tissues, highlighting the need for selective therapies.

Purpose of the Study:

• To review and characterize the diverse targets and mechanisms underlying the antitumor activity of vitamin E succinate (VES).
• To consolidate current understanding of how VES impacts tumor cell behavior and the tumor microenvironment.
• To evaluate the therapeutic promise of VES as a selective anticancer agent.

Main Methods:

• This review synthesizes findings from preclinical and clinical studies investigating VES.
• Mechanisms of action were analyzed through examination of cellular and molecular effects.
• Selectivity was assessed by comparing VES effects on tumor versus normal cells.

Main Results:

• Vitamin E succinate (VES) exhibits pleiotropic intracellular effects, targeting multiple pathways.
• VES effectively induces apoptosis, inhibits proliferation, promotes differentiation, and prevents metastasis in tumor cells.
• Crucially, VES demonstrates minimal toxicity to normal cells and tissues, indicating high selectivity.
• VES also inhibits angiogenesis, a critical process for tumor growth and spread.

Conclusions:

• Vitamin E succinate (VES) possesses a unique combination of broad antitumor activity and remarkable selectivity.
• Its multifaceted mechanisms of action and low toxicity profile position VES as a highly promising agent for developing novel chemotherapeutic strategies against various cancers.
• Further research into VES could pave the way for safer and more effective cancer treatments.